Detected ·
MoonLake Immunotherapeutics
$230M—
Swiss biotech MoonLake Immunotherapeutics (NASDAQ: MLTX) raised $230M in an upsized public offering to advance sonelokimab, a nanobody targeting IL-17A and IL-17F, for inflammatory skin and joint diseases.
- Website
- www.moonlaketx.com
- Amount
- $230 000 000 USD
- Stage
- —
- Event
- Funding round
- Detected
- 2026-07-26 08:01:52 UTC
- Signal ID
- b4fb11c9-b5cc-4636-a84a-7018c2f5b17e
As the API returns it
{
"id": "b4fb11c9-b5cc-4636-a84a-7018c2f5b17e",
"created_at": "2026-07-26T08:01:52.907541Z",
"company_name": "MoonLake Immunotherapeutics",
"company_website_url": "www.moonlaketx.com",
"company_linkedin_url": "https://www.linkedin.com/company/moonlake-immunotherapeutics-ag",
"event_type": "funding",
"funding_amount": 230000000,
"funding_currency": "USD",
"funding_stage": null,
"message": "*Swiss biotech MoonLake Immunotherapeutics (NASDAQ: MLTX) raised $230M in an upsized public offering to advance sonelokimab, a nanobody targeting IL-17A and IL-17F, for inflammatory skin and joint diseases.*"
}